Published in J Biotechnol on January 10, 2007
Monitoring of transcriptional regulation in Pichia pastoris under protein production conditions. BMC Genomics (2007) 1.09
The response to unfolded protein is involved in osmotolerance of Pichia pastoris. BMC Genomics (2010) 1.02
The impact of oxygen on the transcriptome of recombinant S. cerevisiae and P. pastoris - a comparative analysis. BMC Genomics (2011) 0.97
Protein trafficking, ergosterol biosynthesis and membrane physics impact recombinant protein secretion in Pichia pastoris. Microb Cell Fact (2011) 0.95
Quantitative metabolomics analysis of amino acid metabolism in recombinant Pichia pastoris under different oxygen availability conditions. Microb Cell Fact (2012) 0.86
Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J Biol Chem (2009) 0.85
Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study. PLoS One (2012) 0.76
A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix. Sci Rep (2016) 0.75
Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris. AMB Express (2017) 0.75
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med (2005) 5.68
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Microbial production of organic acids: expanding the markets. Trends Biotechnol (2008) 2.88
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis (2004) 2.47
Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics (2008) 2.26
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol (2007) 1.81
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
Stress in recombinant protein producing yeasts. J Biotechnol (2004) 1.76
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
Effects of gene dosage, promoters, and substrates on unfolded protein stress of recombinant Pichia pastoris. Biotechnol Bioeng (2004) 1.64
Genome, secretome and glucose transport highlight unique features of the protein production host Pichia pastoris. Microb Cell Fact (2009) 1.63
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58
Engineering of Pichia pastoris for improved production of antibody fragments. Biotechnol Bioeng (2006) 1.58
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol (2007) 1.56
Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS (2003) 1.55
The effect of temperature on the proteome of recombinant Pichia pastoris. J Proteome Res (2009) 1.53
In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem (2010) 1.52
Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem (2009) 1.49
Polymethacrylate monoliths for preparative and industrial separation of biomolecular assemblies. J Chromatogr A (2008) 1.46
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol (2003) 1.45
Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology (2004) 1.45
Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS (2007) 1.44
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43
Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS (2006) 1.43
Recombinant protein production in yeasts. Methods Mol Biol (2012) 1.41
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol (2004) 1.40
hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol (2008) 1.40
Recombinant protein production in yeasts. Mol Biotechnol (2005) 1.38
Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol (2010) 1.36
Novel insights into the unfolded protein response using Pichia pastoris specific DNA microarrays. BMC Genomics (2008) 1.36
Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J (2007) 1.34
Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses (2006) 1.30
Adaptive laboratory evolution -- principles and applications for biotechnology. Microb Cell Fact (2013) 1.29
A multi-level study of recombinant Pichia pastoris in different oxygen conditions. BMC Syst Biol (2010) 1.28
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother (2006) 1.27
Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol (2010) 1.24
A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics (2009) 1.24
Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses (2004) 1.24
Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol (2009) 1.21
In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol (2007) 1.20
How to join a wave: decision-making processes in shimmering behavior of Giant honeybees (Apis dorsata). PLoS One (2012) 1.20
Pichia pastoris: protein production host and model organism for biomedical research. Future Microbiol (2013) 1.19
Hypoxic fed-batch cultivation of Pichia pastoris increases specific and volumetric productivity of recombinant proteins. Biotechnol Bioeng (2008) 1.19
Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol (2007) 1.18
Versatile modeling and optimization of fed batch processes for the production of secreted heterologous proteins with Pichia pastoris. Microb Cell Fact (2006) 1.18
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS (2002) 1.17
Stereoscopic motion analysis in densely packed clusters: 3D analysis of the shimmering behaviour in Giant honey bees. Front Zool (2011) 1.17
New trends in bioinformatics: from genome sequence to personalized medicine. Exp Gerontol (2003) 1.15
The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol (2003) 1.15
Interaction of U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20 S proteasome. Biochem J (2005) 1.14
Identification and characterisation of novel Pichia pastoris promoters for heterologous protein production. J Biotechnol (2010) 1.13
Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett (2006) 1.13
Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J (2007) 1.13
Differential gene expression in recombinant Pichia pastoris analysed by heterologous DNA microarray hybridisation. Microb Cell Fact (2004) 1.13
Transcriptomics-based identification of novel factors enhancing heterologous protein secretion in yeasts. Appl Environ Microbiol (2007) 1.12
Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol Immunol (2004) 1.11
Macromolecular and elemental composition analysis and extracellular metabolite balances of Pichia pastoris growing at different oxygen levels. Microb Cell Fact (2009) 1.11
Induction without methanol: novel regulated promoters enable high-level expression in Pichia pastoris. Microb Cell Fact (2013) 1.09